A Phase 2 Interventional, Multicenter, Randomized, Open-label Study in Three Age-descending Cohorts to Evaluate Efficacy, Safety and Tolerability of KAF156 and Lumefantrine-SDF Combination in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in a Pediatric Population
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Ganaplacide (Primary) ; Lumefantrine (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Acronyms KALUMI
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 23 Jul 2024 Planned End Date changed from 10 Aug 2024 to 31 Aug 2024.
- 23 Jul 2024 Planned primary completion date changed from 26 Jul 2024 to 19 Aug 2024.
- 12 Jun 2024 Planned End Date changed from 14 Jun 2024 to 10 Aug 2024.